Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Nicox, Novliq ink ophthalmic collaboration
February 2019
SHARING OPTIONS:

SOPHIA ANTIPOLIS, France—Nicox SA and Novaliq GmbH have struck up a research collaboration to develop novel topical ophthalmic formulations of Nicox’s nitric oxide (NO)-donating PDE5 inhibitors based on Novaliq’s water-free enabling EyeSol technology, in pursuit of therapeutics to lower intraocular pressure (IOP). Novaliq will develop and characterize novel formulations for the lead series of NO-donating PDE5 inhibitor compounds with its EyeSol technology. Should they prove successful, Nicox will test the formulations’ ability to lower IOP in preclinical models. No financial terms were disclosed, but the companies will jointly own any newly developed intellectual property that results from this agreement. This deal complements Nicox’s recent decision to focus on topical delivery of NO-donors and their potential in glaucoma.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.